Literature DB >> 31324999

Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.

Kiyonori Kuwahara1, Shigeo Ohba2, Shunsuke Nakae1, Natsuki Hattori1, Eriel Sandika Pareira3, Seiji Yamada4, Hikaru Sasaki3, Masato Abe5, Mitsuhiro Hasegawa1, Yuichi Hirose1.   

Abstract

The genetic features of isocitrate dehydrogenase-wild-type (IDH-wt) lower-grade gliomas (LGGs; World Health Organization grades II and III) are not well defined. This study analyzed the genetic and other features of IDH-wt LGGs to develop a subclassification that can be used to predict their prognosis. Clinical, histopathological, and genetic features of 35 cases of diffuse IDH-wt astrocytoma and IDH-wt anaplastic astrocytoma were analyzed. The following genetic factors were examined: mutations of B-rapidly accelerated fibrosarcoma, telomerase reverse transcriptase promoter (TERTp), histone 3 family 3A, and alpha-thalassemia/mental retardation syndrome, X-linked; and copy number aberrations. In the univariate analysis, the following factors were associated with poor overall survival (OS): the histopathological diagnosis, TERTp mutation, the gain of chromosome 7 (+ 7), and the loss of chromosome 10q (- 10q). In the multivariate analysis, + 7, - 10q, and TERTp mutation were independent prognostic factors associated with poor OS. The median OS was significantly worse for patients who harbored at least one of these factors than for those without any of them (18.5 vs. 54.5 months, P = 0.002). The subclassification of IDH-wt LGGs according to the genetic factors + 7, - 10q, and TERTp mutation is potentially useful for predicting the prognosis.

Entities:  

Keywords:  Chromosome 10; Chromosome 7; Glioma; IDH-wild-type; TERT promoter

Mesh:

Substances:

Year:  2019        PMID: 31324999     DOI: 10.1007/s10014-019-00348-9

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  4 in total

Review 1.  Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications.

Authors:  Valeria Internò; Giacomo Triggiano; Pierluigi De Santis; Luigia Stefania Stucci; Marco Tucci; Camillo Porta
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

Review 2.  Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.

Authors:  Takashi Komori
Journal:  Lab Invest       Date:  2021-09-09       Impact factor: 5.662

3.  FABP5 enhances malignancies of lower-grade gliomas via canonical activation of NF-κB signaling.

Authors:  Yichang Wang; Alafate Wahafu; Wei Wu; Jianyang Xiang; Longwei Huo; Xudong Ma; Ning Wang; Hao Liu; Xiaobin Bai; Dongze Xu; Wanfu Xie; Maode Wang; Jia Wang
Journal:  J Cell Mol Med       Date:  2021-04-09       Impact factor: 5.310

4.  Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience.

Authors:  Uiju Cho; Seung Ho Yang; Changyoung Yoo
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.573

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.